Ornithine Canon, 3 g 10 pcs

Pharmacotherapeutic group

Phypoazotemic agent

ATX code: A05BA

Pharmacological properties

It has detoxifying action, reducing elevated ammonia levels in the body, in particular in liver diseases. The action of the drug is associated with its participation in the ornithine cycle of urea formation of Krebs (activates the cycle by restoring the activity of liver cells enzymes: ornithine carbamoyltransferase and carbamoylphosphate synthase). Promotes the production of insulin and somatotropic hormone. Improves protein metabolism in diseases requiring parenteral nutrition. Helps to reduce asthenic, dyspeptic and pain syndromes, as well as normalization of increased body weight (in steatosis and steatohepatitis).

Pharmacokinetics

L-ornithine-L-aspartate quickly dissociates into its components – ornithine and aspartate, and starts working within 15-25 minutes with a short half-life. It is excreted with the urine through the urea cycle.

Indications

Active ingredient

Composition

Active ingredient:

L-ornithine-L-aspartate 3 g.

Auxiliary Ingredients:

Lemon flavoring 0.015 g,

Mint flavoring 0.005 g,

p> aspartame 0.05 g,

citric acid anhydrous 0.5 g,

mannitol 1.430 g.

How to take, the dosage

Special Instructions

When hepatic encephalopathy is diagnosed due to an underlying disease, increased caution should be exercised when driving motor vehicles and engaging in other potentially hazardous activities requiring increased concentration and rapid psychomotor reactions.

Impact on driving and operating ability

The drug Ornithine Canon has no effect on the ability to drive vehicles or engage in other potentially dangerous activities.

Contraindications

Extended renal insufficiency with a creatinine index greater than

3 mg/100 ml, hypersensitivity to the components of the drug, lactation, children under 18 years of age (due to insufficient data).

With caution

Pregnancy.

Side effects

The frequency of adverse reactions is presented according to the following classification (classification of the World Health Organization):

infrequent from > 1/1000 to < 1/100,

very rare from < 1/10000, including individual reports,

frequency unknown (frequency cannot be calculated from available data).

Immune system disorders

frequency unknown: allergic reactions.

Gastrointestinal disorders

infrequent: nausea, vomiting, abdominal pain, flatulence, diarrhea.

Muscular and connective tissue disorders

very rarely: pain in the extremities.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

Similarities